Waiver Extension Doubles Down on a Failed Experiment at the Expense of American MaritimeJobs

NEW ORLEANS — Aug. 10, 2026 — The Offshore Marine Service Association (OMSA) is responding to the Trump administration's decision to extend the current Jones Act waiver despite clear evidence it has failed to lower fuel prices while continuing to undermine American marit...
Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026

- FDA confirmed the resubmission is a complete, Class II response to the Aug. 27, 2025 CRL.
New Housing Law Could Open Doors for Homebuyers and Individual Real Estate Investors

Global Real Estate Veteran Angela Healy says increasing housing supply remains critical to affordability and workforce growth
OMSA Calls on Congress to End Regulatory Disparities Hurting U.S.-Flagged Vessels

Restated Marine Safety Mission and New Civilian Secretary of the Coast Guard proposed as solutions 
BrightDot Founder and CEO Bill Crouch Releases New Book: “Mattership™: Making Donors Feel They Matter”

New book reframes fundraising as relationship-building, not transaction-chasing
Statement from James Dismond, CEO of MiraSol Health on CMS’ Proposed Palliative Care Policy

BLUFFTON, S.C., July 20, 2026 -- "The Centers for Medicare & Medicaid Services’s proposal to recognize community-based palliative care under the Medicare home health benefit is one of the most significant federal policy developments we've seen for serious illness car...
Atrium Health and OrthoCarolina join forces to build nationally recognized orthopedic destination

Expanded collaboration builds on a longstanding relationship to advance access, coordinated care, education and innovation
Mighty Therapeutics Announces First Patient Dosed in Phase 4 Confirmatory Study of Elamipretide in Barth Syndrome

– Comprehensive updates to be presented at Barth Syndrome Foundation conference –
Saol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Disease
Existing data supports direct path to resubmission following constructive FDA engagement
AvenueWest Global Named to Inc. 5000 List for Eighth Time

Company Recognized for 167% Three-Year Revenue Growth, Earning a Place Among the Nation’s Most Successful Independent Businesses
Waiver Extension Doubles Down on a Failed Experiment at the Expense of American MaritimeJobs

NEW ORLEANS — Aug. 10, 2026 — The Offshore Marine Service Association (OMSA) is responding to the Trump administration's decision to extend the current Jones Act waiver despite clear evidence it has failed to lower fuel prices while continuing to undermine American marit...
Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026

- FDA confirmed the resubmission is a complete, Class II response to the Aug. 27, 2025 CRL.
New Housing Law Could Open Doors for Homebuyers and Individual Real Estate Investors

Global Real Estate Veteran Angela Healy says increasing housing supply remains critical to affordability and workforce growth
OMSA Calls on Congress to End Regulatory Disparities Hurting U.S.-Flagged Vessels

Restated Marine Safety Mission and New Civilian Secretary of the Coast Guard proposed as solutions 
BrightDot Founder and CEO Bill Crouch Releases New Book: “Mattership™: Making Donors Feel They Matter”

New book reframes fundraising as relationship-building, not transaction-chasing
Statement from James Dismond, CEO of MiraSol Health on CMS’ Proposed Palliative Care Policy

BLUFFTON, S.C., July 20, 2026 -- "The Centers for Medicare & Medicaid Services’s proposal to recognize community-based palliative care under the Medicare home health benefit is one of the most significant federal policy developments we've seen for serious illness car...
Atrium Health and OrthoCarolina join forces to build nationally recognized orthopedic destination

Expanded collaboration builds on a longstanding relationship to advance access, coordinated care, education and innovation
Mighty Therapeutics Announces First Patient Dosed in Phase 4 Confirmatory Study of Elamipretide in Barth Syndrome

– Comprehensive updates to be presented at Barth Syndrome Foundation conference –
Saol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Disease
Existing data supports direct path to resubmission following constructive FDA engagement

Subscribe

Let's stay in touch!
1
2
3
4
5
6
7